Molecules that selectively home to vasculature of...

Details Molecules that selectively home to vasculature of... Molecules that selectively home to vasculature of...

2004-10-29

2009-10-06

Helms, Larry R. (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S350000, C530S329000, C530S324000

Reexamination Certificate

active

07598341

ABSTRACT:
The invention provides a conjugate that includes a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to vasculature of premalignant pancreas. The peptide or peptidomimetic contains at least 5 contiguous amino acids of an amino acid sequence selected from CRSRKG (SEQ ID NO:9) and CEYQLDVE (SEQ ID NO:34), or a conservative variant or peptidomimetic thereof. The invention additionally provides a conjugate containing a therapeutic moiety linked to a peptide or peptidomimetic that selectively homes to pancreatic tumor cells and pancreatic tumor vasculature, the peptide or peptidomimetic comprising at least 5 contiguous amino acids of an amino acid sequence selected from CKAAKNK (SEQ ID NO:15), CKGAKAR (SEQ ID NO:19), and VGVGEWSV (SEQ ID NO:35), or a conservative variant or peptidomimetic thereof.

REFERENCES:
patent: 5144006 (1992-09-01), Tam
patent: 5662699 (1997-09-01), Hamedi et al.
patent: 5789542 (1998-08-01), McLaughlin et al.
patent: 6068829 (2000-05-01), Ruoslahti et al.
patent: 6174687 (2001-01-01), Rajotte et al.
patent: 6180084 (2001-01-01), Ruoslahti et al.
patent: 6232287 (2001-05-01), Ruoslahti et al.
patent: 6296832 (2001-10-01), Ruoslahti et al.
patent: 6303573 (2001-10-01), Ruoslahti et al.
patent: 6306365 (2001-10-01), Ruoslahti et al.
patent: 6491894 (2002-12-01), Ruoslahti et al.
patent: 6528481 (2003-03-01), Burg et al.
patent: 6610651 (2003-08-01), Ruoslahti et al.
patent: 6743892 (2004-06-01), Ruoslahti et al.
patent: 6784153 (2004-08-01), Rajotte et al.
patent: 6933281 (2005-08-01), Ruoslahti et al.
patent: 7018615 (2006-03-01), Ruoslahti et al.
patent: 7144860 (2006-12-01), Ruoslahti et al.
patent: 7192921 (2007-03-01), Laakkonen et al.
patent: 2003/0055236 (2003-03-01), Moore et al.
patent: 2005/0064507 (2005-03-01), Shaw
patent: WO/97/10507 (1997-03-01), None
patent: WO/98/10795 (1998-03-01), None
patent: WO/99/46284 (1999-09-01), None
patent: WO/00/42973 (2000-07-01), None
patent: WO/00/48464 (2000-08-01), None
patent: WO/00/75174 (2000-12-01), None
patent: WO0168679 (2001-09-01), None
Schraa et al., J control release, vol. 83, p. 241-51, Oct. 4, 2002, abstract.
Database A-Geneseq No. AAY36559.
Database A-Geneseq No. ADU17039.
Sequence search results (SEQ ID No. 5, 9, 15).
Porkka et al., PNAS, vol. 99, p. 7444-7449, 200.
Alvarez-Bravo et al., “Novel synthetic antimicrobial peptides effective against methicillin-resistantStaphylococcus aureus,” Biochem. J. 302:535-538 (1994).
Arap et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,”Science279:377-380 (1998).
Bergers et al., “Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis,”Int. J. Dev. Biol. 42:995-1002 (1998).
Bergers et al., “Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors,”J. Clin. Invest. 111:1287-1295 (2003).
Bergers et al., “Effects of angiogenesis inhibitors on multistage carcinogenesis in mice,”Science284:808-812 (1999).
Bergsten et al., “PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor,”Nat. Cell Biol. 3:512-516 (2001).
Bessalle et al., “All-D-magainin: chirality, antimicrobial activity and proteolytic resistance,”FEBS Lett. 274:151-155 (1990).
Blondelle and Houghten, “Design of model amphipathic peptides having potent antimicrobial activities,”Biochem. 31:12688-12694 (1992).
Blondelle and Houghten,Annual Reports in Medicinal Chemistry, Academic Press, San Diego, 159-168, (1992).
Boehm et al., “Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance,”Nature390:404-407 (1997).
Bohme et al., “Primary structure of the long and short splice variants of mouse collagen XII and their tissue-specific expression during embryonic development,”Dev. Dyn. 204:432-445 (1995).
Castronovo and Belotti, “TNP-470 (AGM-1470): mechanisms of action and early clinical development,”Eur. J. Cancer32A:2520-2527 (1996).
Chan et al., “Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer,”J. Clin. Oncol. 17:2341-2354 (1999).
Chaudhry et al., “Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system,”Cancer Research, 52:1006-1012 (1992).
Crown, “The platinum agents: a role in breast cancer treatment?”Seminars in Oncol. 28:28-37 (2001).
Efrat et al., “Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene,”Proc. Natl. Acad. Sci. USA85:9037-9041 (1988).
Folkman et al., “Induction of angiogenesis during the transition from hyperplasia to neoplasia,”Nature339:58-61 (1989).
Gohring et al., “Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope,”Eur. J. Biochem. 255:60-66 (1998).
Griffith et al., Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin,Chem Biol. 4:461-471 (1997).
Hagedorn and Bikfalvi, “Target molecules for anti-angiogenic therapy: from basic research to clinical trials,”Crit. Rev. Oncol. Hematol. 34:89-110 (2000).
Hanahan, “Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes,”Nature315:115-122 (1985).
Hashizume et al, “Openings between defective endothelial cells explain tumor vessel leakiness,”Am. J. Pathol. 156:1363-1380 (2000).
Homandberg et al., “Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth,”Am. J. Path. 120:327-332 (1985).
Homandberg, et al., “Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth: structure-function correlations,”Biochim. Biophys. Acta874:61-71 (1986).
Ingber et al., “Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth,”Nature348:555-557 (1990).
Javadpour et al., “De novo antimicrobial peptides with low mammalian cell toxicity,”J. Med. Chem. 39:3107-3113 (1996).
Johnsson et al., “The c-sis gene encodes a precursor of the B chain of platelet-derived growth factor,”EMBO J. 3:921-928 (1984).
Kirsch et al., “Anti-angiogenic treatment strategies for malignant brain tumors,”J. Neurooncol. 50:149-163 (2000).
Laakkonen et al., “A tumor-homing peptide with a targeting specificity related to lymphatic vessels,”Nat. Med. 8:751-755 (2002).
Larochelle et al., “PDGF-D, a new protease-activated growth factor,”Nat. Cell Biol. 3:517-521 (2001).
Lopez and Hanahan, “Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis,”Cancer Cell1:339-353 (2002).
Maloy and Kari, “Structure-activity studies on magainins and other host defense peptides,”Biopolymers37:105-122 (1995).
Mancheno et al., “A peptide of nine amino acid residues from alpha-sarcin cytotoxin is a membrane-perturbing structure,”J. Peptide Res. 51:142-148 (1998).
Morikawa et al., Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors,Am. J. Pathol. 160:985-1000 (2002).
O'Reilly et al., “Angiostatin induces and sustains dormancy of human primary tumors in mice”Nature Med. 2:689-692 (1996).
O'Reilly et al., “Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma,”Cell79:315-328 (1994).
O'Reilly et al., “Antiangiogenic activity of the cleaved conformation of the serpin antithrombin,”Science285:1926-1928 (1999).
O'Reilly et al., “Endostatin: an endogenous inhibitor of angiogenesi

Affiliated with

Also associated with

Rating

Molecules that selectively home to vasculature of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Molecules that selectively home to vasculature of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecules that selectively home to vasculature of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4073668